Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $65.1 million.

  • Zevra Therapeutics' Gains from Investment Securities rose 5742.89% to $65.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $222.5 million, marking a year-over-year increase of 43638.05%. This contributed to the annual value of $6.0 million for FY2024, which is 2582.21% down from last year.
  • Per Zevra Therapeutics' latest filing, its Gains from Investment Securities stood at $65.1 million for Q3 2025, which was up 5742.89% from $150.4 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Gains from Investment Securities registered a high of $150.4 million during Q2 2025, and its lowest value of -$10.5 million during Q1 2022.
  • In the last 5 years, Zevra Therapeutics' Gains from Investment Securities had a median value of $39000.0 in 2021 and averaged $16.9 million.
  • In the last 5 years, Zevra Therapeutics' Gains from Investment Securities tumbled by 1729016.39% in 2022 and then skyrocketed by 11645271.32% in 2025.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Gains from Investment Securities stood at $17000.0 in 2021, then tumbled by 2447.06% to -$399000.0 in 2022, then soared by 98.25% to -$7000.0 in 2023, then tumbled by 4571.43% to -$327000.0 in 2024, then skyrocketed by 20011.62% to $65.1 million in 2025.
  • Its last three reported values are $65.1 million in Q3 2025, $150.4 million for Q2 2025, and $7.4 million during Q1 2025.